Liftstream is an executive search recruitment company in the life sciences sector
NPS Pharma submits BLA for Natpara
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged bioengineered, Biologic License Application, biotechnology, BLA, EMA, FDA, Francois Nader, Gattex, Hypoparathyroidism, Naptara, NPS Pharmaceuticals, Orphan drugs, patient registry, pharmaceutical, phase III clinical trials, Rare Disease, Revestive
Leave a comment
Aegerion and NPS Pharmaceuticals begin rare disease product launches
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Aegerion Pharma, CHMP positive opinion, commercial opportunities, commercialisation, Dan Rader, Dick Gregg, EMA, europe, Gattex, HoFH, Juxtapid, LOJUXTA, novel therapies, NPS pharma, orphan designation, Orphan drugs, Rare Disease, Revestive, short bowel syndrome, Takeda, USA
Leave a comment
13 Life Science Leaders to watch in 2013
Authored by Liftstream
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Abbott, AbbVie, Amgen, Angus Russell, AstraZeneca, Bluebird bio, Cancer Vaccine, CEO, Cystic Fibrosis, Dalvir Gill, David Mott, Director General EFPIA, EFPIA, EMEA, Erbitux, FDA, Flemming Ornskov, Foundation Medicine, FoundationOne, Gattex, Gene therapy, Gilead Sciences, Glybera, HCV, Hepatitis, Humira, INSPIRE, Jeff Leiden, Jeremy Levin, John Martin, Kalydeco, Karl-Ludwig Kley, Lotus Tissue Repair, Merck KGaA, Michael Pellini, Natpara, New Enterprise Associates, NP Pharmaceuticals, oncology, Orphan drugs, Pascal Soriot, rare diseases, Richard Bergstrom, Richard Gonzalez, Shire, Shire Speciality pharma, Sofosbuvir, Stimuvax, Takeda, Teva, TransCelerate, Ultragenyx, uniQure, Vertex Pharmaceuticals, Vyvanse
Leave a comment
NPS Pharmaceuticals gets ready to launch gastro orphan drug
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases
Tagged commercial, endocrinology, europe, FDA, gastroenterology, Gattex, hormone, Market Access, marketing, Natpara, NPS Pharmaceuticals, Nycomed, Orphan Drug, patients, pricing and reimbursement, Revestive, short bowel syndrome, Takeda, teduglutide, ultra-rare diseases, USA
Leave a comment